BC Innovations | Jul 10, 2018
Distillery Therapeutics


INDICATION: Melanoma, colorectal cancer In vitro , cell culture and mouse studies identified an aminopyrimidine-based dual MAPK1/MAPK3 inhibitor that could help treat BRAF-mutant melanoma and colorectal cancer. Fragment-based screening, chemical synthesis and in vitro enzyme activity...
BC Week In Review | May 12, 2014
Clinical News

Aeterna Zentaris preclinical data

In vitro, AEZS-134 led to growth inhibition of tumor cells resistant to MEK and Raf inhibitors. Data were presented at the American Association for Cancer Research meeting in San Diego. Aeterna Zentaris said it has...
Items per page:
1 - 2 of 2